Owners and Capital

Owners and Capital

EPAM is founder-led in spirit but institutionally owned in fact. Co-founder Arkadiy Dobkin holds 2.9% of the stock and the entire insider group 3.8%; four index and active managers hold more than a third [1]. Into an ~88% decline, insiders were net sellers, not buyers. The clearest vote of confidence has come not from their wallets but from the company's own cash: buybacks of roughly $1.2 billion across three years, retiring stock at falling prices.

Ownership: a founder with a small stake, and institutions in control

As of March 2026 there were 52,444,312 shares outstanding. The founder's holding is the largest inside the company but small in absolute terms, and it sits well below the stakes of the passive and active funds that dominate the register [2].

Source: 2026 Proxy Statement (DEF 14A), Security Ownership of Certain Beneficial Owners & Management [3].

This matters for how a reader frames the case. A company where a founder owns a controlling block and personally absorbs the drawdown is a different proposition from one where a professional management team stewards other people's capital. EPAM is the latter. Dobkin stepped back from the CEO role in 2025 — Balazs Fejes now runs the company, with Dobkin as Executive Chair — and no insider owns enough to steer an outcome the institutions oppose. The founder's stake has also drifted lower over time, from 4.4% in 2019 to 3.4% in 2022, 3.5% in 2024, and 2.9% today, as he sold, gifted, and had shares withheld for taxes on vesting [4] [5] [6].

Source: EPAM proxy statements, Security Ownership tables, 2019–2026 [7] [8] [9] [10].

No insider buying at the lows

For a reader drawn to insider alignment, the transaction record is the more telling test than the static stake. Across mid-2023 through mid-2026 — the period spanning the second leg of the decline — insiders sold roughly $33 million of stock in discretionary open-market sales and bought almost nothing: about $0.16 million, in small recurring lots that carry the signature of routine employee stock-purchase-plan participation rather than opportunistic buying [11]. Not one officer or director stepped in to buy the stock at its lows.

Source: derived from SEC Form 4 filings, June 2023–May 2026 [12].

The counter-fact matters, and it is favorable to management's timing. The single largest seller was Dobkin himself, who sold 39,300 shares for about $11.9 million — but he did so in March 2024, at $300 to $307 a share, near a local high, and has made no discretionary open-market sale since; his later dispositions are mechanical share-withholding on vesting and option exercises [13]. So the record is not one of executives dumping stock into a falling market. It is the milder but still relevant absence of the opposite signal: with the shares down to roughly a quarter of that 2024 level, no insider has treated them as a bargain worth adding to personally. The "insiders think it's cheap" leg of a value case is simply not present here.

Compensation: mostly equity, well-supported, with one quirk

Pay is structured the way a professional investor would want: heavily weighted to equity, split evenly between performance stock units and time-vested restricted stock, with no employment agreements (bar a Swiss-law requirement for Fejes), no golden parachutes, a clawback policy, and prohibitions on hedging or pledging the stock [14] [15]. Absolute levels are moderate for a $5.5 billion-revenue S&P 500 company. Shareholders agree: the 2025 say-on-pay vote drew roughly 94% support [16].

Source: 2026 Proxy Statement (DEF 14A), Summary Compensation Table [17].

The quirk sits in the top row. Dobkin, having handed over the CEO title in 2025, was still the highest-paid executive that year at $8.1 million — above the sitting CEO's $5.2 million [18]. An Executive Chair out-earning the CEO is worth flagging; it is not disqualifying, and it may reflect a transition year, but a reader tracking whether the succession is real should watch whether the gap narrows in 2026.

The pay ratio is a lens on the delivery model as much as on pay. The median EPAM employee earned $38,570 in 2025, and the CEO-to-median ratio was 186:1, down from 219:1 in 2024 [19] [20]. The low median reflects a workforce that is roughly 95% outside the United States — the offshore-heavy cost base that is the company's core economic advantage, and the same labor pool whose billable hours the AI-deflation debate (AI Demand and Deflation) is about.

Capital allocation: countercyclical buybacks, and one large bet

With no dividend, EPAM's capital-return story is entirely the buyback — and the buyback has grown as the stock has fallen. The company spent $164.9 million on repurchases in 2023, $398.0 million in 2024, and $660.6 million in 2025, retiring every share bought [21]. The average price paid fell from about $215 a share in 2024 to about $187 in 2025 as management leaned in at lower prices, and in October 2025 the board authorized a fresh $1.0 billion program, $776.5 million of which remained at year-end [22] [23].

Sources: FY2025 Annual Report (Form 10-K), Consolidated Statements of Cash Flows and Share Repurchases note [24] [25]; FY2023 acquisitions per FY2024 10-K [26].

Because buybacks have outrun the modest dilution from stock compensation, options, and the employee purchase plan, the share count has actually fallen — from 57.8 million at the end of 2023 to 54.3 million at the end of 2025 [15]. In 2025 alone repurchases of about $662 million exceeded free cash flow of roughly $613 million, so the company returned more than its cash generation for the year, drawing modestly on its balance sheet to do so [27].

Source: FY2025 Annual Report (Form 10-K), Consolidated Statements of Changes in Stockholders' Equity [15].

The other side of the ledger is the acquisition bet. In 2024 EPAM deployed about $912 million of cash on acquisitions — chiefly NEORIS and First Derivative — draining its cash pile from $2.04 billion to $1.29 billion in a single year [28]. That choice bought most of 2025's reported growth (the acquisitions added roughly nine points to a 15.4% headline), but it also converted an interest-earning cash balance into operating businesses — and the lost interest income was about two-thirds of the year's GAAP earnings decline (Financials and Estimates). So management ran two capital programs at once through the downturn: buying its own shares at depressed prices while spending nearly a billion dollars to bulk up organically-slow revenue with bought growth. The buyback is straightforwardly value-accretive at these multiples; the acquisitions are the item a skeptic should keep testing, because their margin and returns are what determine whether the cash was well spent — the deal economics (goodwill weighting, price paid relative to sales, and earnings contribution to date) are set out in Margin of Safety.

What this establishes

On the reader's alignment test, the honest read is mixed. Governance is clean and shareholder-responsive — even-handed pay, near-unanimous say-on-pay, a separated chair and CEO, a board that has been declassifying and stripping out supermajority provisions under stockholder pressure [29]. But the "strong owner-operator with skin in the game" pattern does not fit: the founder owns under 3% and is stepping back, the insider group owns under 4%, and nobody inside has bought the stock on the way down. The conviction on display is corporate, not personal — the balance sheet retiring 6% of the shares in three years. That is a real signal, but it is management spending shareholders' cash, not risking their own. The main risk to reading the buyback as smart countercyclical capital return is the parallel $912 million acquisition bet: if those businesses underperform, the same team will have spent the cash cushion at exactly the wrong time.